FDA panel greenlights broader access to six controversial peptides
An FDA Pharmacy Compounding Advisory Committee voted to recommend loosening regulations on six peptide therapies—BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500—potentially enabling prescription-based access if the FDA approves; supporters hail a win for personalized medicine, but FDA scientists have warned there isn’t enough data on safety and efficacy, and a final decision could take months.